Dietary Melatonin Protects Against Behavioural, Metabolic, Oxidative, and Organ Morphological Changes in Mice that are Fed High-Fat, High- Sugar Diet

2020 ◽  
Vol 20 (4) ◽  
pp. 570-583
Author(s):  
Adejoke Yetunde Onaolapo ◽  
Ebenezer Oladimeji Adebisi ◽  
Adegbayi Emmanuel Adeleye ◽  
Anthony Tope Olofinnade ◽  
Olakunle James Onaolapo
Keyword(s):  
Metabolic Syndrome ◽  
Body Weight ◽  
Spatial Working Memory ◽  
Morphological Changes ◽  
Organ Injury ◽  
Standard Diet ◽  
High Fat ◽  
High Sugar ◽  
The Metabolic Syndrome ◽  
Increased Risk

Background : Metabolic syndrome is a complex pattern of disorders that occur jointly and is associated with an increased risk of cardiovascular and cerebrovascular disease. Therefore the need for more-efficient options of treatment has become imperative. Objective : This study examined the effect of dietary-melatonin in the management of behavioural, metabolic, antioxidant, and organ changes due to high-fat/high-sugar (HFHS) diet-induced metabolic syndrome in mice. Methods: Mice were randomly assigned into five groups of ten animals each. Groups were normal control [fed standard diet (SD)], HFHS control, and 3 groups of melatonin incorporated into HFHS at 2.5, 5, and 10 mg/kg of feed. Mice were fed for seven weeks, and body weight was assessed weekly. Open-field behaviours, radial-arm, and Y-maze spatial memory were scored at the end of the experimental period. Twenty-four hours after the last behavioural test, blood was taken for estimation of blood glucose levels after an overnight fast. Animals were then euthanised, and blood was taken for estimation of plasma insulin, leptin, and adiponectin levels, and serum lipid profile. The liver, kidneys, and brain were excised and processed for general histology, while homogenates of the liver and whole brain were used to assess oxidative stress parameters. Results: Results showed that dietary melatonin (compared to HFHS diet) was associated with a decrease in body weight, food intake, and novelty-induced behaviours; and an increase in spatial-working memory scores. A decrease in glucose, insulin, leptin, and malondialdehyde levels; and an increase in adiponectin levels and superoxide dismutase activity were also observed. Histomorphological/ histomorphometric examination revealed evidence of organ injury with HFHS diet, and varying degrees of amelioration with melatonin-supplemented diet. Conclusion: In conclusion, dietary melatonin supplementation may have beneficial effects in the management of the metabolic syndrome..

Lepidium Meyenii Supplemented Diet Modulates Neurobehavioral and Biochemical Parameters in Mice Fed High-Fat-High-Sugar Diet

2020 ◽  
Vol 20 ◽  
Author(s):  
Anthony T. Olofinnade ◽  
Abiola Alawode ◽  
Adejoke Y. Onaolapo ◽  
Olakunle J. Onaolapo
Keyword(s):  
Oxidative Stress ◽  
Metabolic Syndrome ◽  
Body Weight ◽  
Inflammatory Markers ◽  
Acetylcholinesterase Activity ◽  
Standard Diet ◽  
High Fat ◽  
Lepidium Meyenii ◽  
High Sugar ◽  
Increased Risk

Background: Metabolic syndrome has been associated with increased risk of cardiovascular disease, diabetes mellitus, and neurodegenerative disorders. Known side-effects of currently-available drugs necessitate the search for possibly better treatment options. Objective: This study examined the effects of dietary lepidium meyenii (MACA) supplementation on neurobehaviour, metabolic profile, levels of inflammatory markers, and oxidative stress parameters in a mouse model of metabolic syndrome. Methodology: Mice were randomly-assigned into 8 groups of ten animals each. Groups consist of standard diet (SD) control, high fat/high sugar (HFHS) control and three groups each of lepidium meyenii incorporated into either SD or HFHS diet at 0.1, 0.2 and 0.4 %. Mice were fed for seven weeks, and body weight was measured weekly. Open-field behaviors and radial-arm/Y-maze spatial memory were scored at the end of the study. Twenty-four hours after the last behavioral test, fasting blood glucose levels were estimated. Animals were then euthanized, and blood taken for estimation of serum lipid profile. Whole brains were excised, weighed and homogenized for the estimation of levels of lipid peroxidation, inflammatory markers, antioxidant status, and acetylcholinesterase activity. Results: MACA-supplemented diet was associated with a decrease in body weight gain, an increase in food intake (at lower concentrations), suppression of grooming behavior, and decrease in acetylcholinesterase activity. MACA-supplement also reversed HFHS-induced memory impairment, anxiety, hyperglycaemia, lipid derangement, oxidative stress, and derangement of inflammatory markers. Conclusion: Dietary supplementation with MACA shows beneficial effects in mitigating the effects of metabolic syndrome on the brain in mice.

scholarly journals The effect of venlafaxine on blood pressure and ECG in rats fed with high-fat-fructose diet

2019 ◽  
Vol 12 (4) ◽  
pp. 192-199
Author(s):  
Michaela Sasváriová ◽  
Dominika Micháliková ◽  
Barbara Tyukos Kaprinay ◽  
Lazaros Salvaras ◽  
Slavomila Hričáková ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Body Weight ◽  
Heart Weight ◽  
Standard Diet ◽  
Qtc Interval ◽  
High Fat ◽  
Major Health ◽  
The Metabolic Syndrome ◽  
Body Weight Index

AbstractMetabolic syndrome represents one of the major health, social and economic issues nowadays, and affects more than 25% people worldwide. Being a multifactorial health problem, metabolic syndrome clusters various features, such as obesity, dyslipidemia, hyperglycemia and hypertension. Each of these disturbances represents a risk factor for developing cardiovascular disease. Moreover, patients with metabolic syndrome are more likely to suffer from depression, thus treatment with antidepressants (e.g. venlafaxine) is often neccessary. However, many of the antidepressants themselves may contribute to worsening or even development of the metabolic syndrome, thus creating a “vicious circle”. The aim of this work was to investigate on the animal model of metabolic syndrome, i.e. on hypertriacylglycerolemic rats fed high-fat-fructose diet (HFFD): 1) the effect of a change in diet from HFFD to a standard diet (SD) and the effect of venlafaxine treatment, 2) during HFFD, 3) as well as during a changed diet to SD. We focused on biometric parameters, blood pressure and selected ECG parameters. We observed the reversibility of the present metabolic and cardiovascular changes by switching the HFFD to SD in the last 3 weeks of the experiment. Switch to the standard diet led to decrease of body weight, even in the presence of venlafaxine. Administration of venlafaxine caused the decrease of heart weight/body weight index in rats fed with HFFD compared to the untreated group fed with HFFD for 8 weeks. Blood pressure, which was increased in the HFFD group showed a tendency to decrease to control values after switching to the standard diet. Administration of venlafaxine led to significant increase in all parameters of blood pressure when rats were fed with HFFD throughout the whole experiment. In untreated rats fed with HFFD for 8 weeks, we observed a shorter PQ interval and prolonged QRS complex as well as QTc interval compared to untreated rats with diet switched to SD. This effect was potentiated by venlafaxine administered not only during HFFD but even after switch to SD. Our results point to the fact that metabolic syndrome is clearly affecting the function of the cardiovascular system by modifying blood pressure and electrical activity of the heart. Moreover, administration of venlafaxine may lead to worsening of the observed changes, especially in the presence of high-fat-fructose diet.

scholarly journals 7-Hydroxymatairesinol improves body weight, fat and sugar metabolism in C57BJ/6 mice on a high-fat diet

2018 ◽  
Vol 120 (7) ◽  
pp. 751-762 ◽  
Author(s):  
Giorgio Biasiotto ◽  
Isabella Zanella ◽  
Federica Predolini ◽  
Ivonne Archetti ◽  
Moris Cadei ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Body Weight ◽  
High Fat Diet ◽  
Sugar Metabolism ◽  
Lipid Uptake ◽  
High Fat ◽  
Total Extract ◽  
The Metabolic Syndrome ◽  
Metabolic Genes

Abstract7-Hydroxymatairesinol (7-HMR) is a plant lignan abundant in various concentrations in plant foods. The objective of this study was to test HMRLignan™, a purified form of 7-HMR, and the correspondingPicea abiesextract (total extractP. abies; TEP) as dietary supplements on a background of a high-fat diet (HFD)-induced metabolic syndrome in mice and in the 3T3-L1 adipogenesis model. Mice, 3 weeks old, were fed a HFD for 60 d. Subgroups were treated with 3 mg/kg body weight 7-HMR (HMRLignan™) or 10 mg/kg body weight TEP by oral administration. 7-HMR and TEP limited the increase in body weight (−11 and −13 %) and fat mass (−11 and −18 %) in the HFD-fed mice. Epididymal adipocytes were 19 and −12 % smaller and the liver was less steatotic (−62 and −65 %). Serum lipids decreased in TEP-treated mice (−11 % cholesterol, −23 % LDL and −15 % TAG) and sugar metabolism was ameliorated by both lignan preparations, as shown by a more than 70 % decrease in insulin secretion and insulin resistance. The expression of several metabolic genes was modulated by the HFD with an effect that was reversed by lignan. In 3T3-L1 cells, the 7-HMR metabolites enterolactone (ENL) and enterodiol (END) showed a 40 % inhibition of cell differentiation accompanied by the inhibited expression of the adipogenic genesPPARγ,C/EBPαandaP2. Furthermore, END and ENL caused a 10 % reduction in TAG uptake in HEPA 1–6 hepatoma cells. In conclusion, 7-HMR and TEP reduce metabolic imbalances typical of the metabolic syndrome and obesity in male mice, whereas their metabolites inhibit adipogenesis and lipid uptakein vitro.

scholarly journals Chronic Stress, Combined with a High-Fat/High-Sugar Diet, Shifts Sympathetic Signaling toward Neuropeptide Y and Leads to Obesity and the Metabolic Syndrome

2008 ◽  
Vol 1148 (1) ◽  
pp. 232-237 ◽  
Author(s):  
Lydia E. Kuo ◽  
Magdalena Czarnecka ◽  
Joanna B. Kitlinska ◽  
Jason U. Tilan ◽  
Richard Kvet��ansk�� ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Neuropeptide Y ◽  
Chronic Stress ◽  
High Fat ◽  
High Sugar ◽  
The Metabolic Syndrome ◽  
Diet Shifts

scholarly journals Etlingera elatior (Jack) R.M, Sm Containing Diet Normalizes some Metabolic Syndrome Markers due to High-Fat High-Fructose Diet in Wistar Rats

2020 ◽  
Vol 16 ◽  
Author(s):  
Nur Islami Dini Hanifah ◽  
Retno Murwani ◽  
Achmad Zulfa Juniarto
Keyword(s):  
Metabolic Syndrome ◽  
Body Weight ◽  
Total Cholesterol ◽  
Wistar Rats ◽  
Density Lipoprotein ◽  
Standard Diet ◽  
High Fat ◽  
High Fructose Diet ◽  
High Fructose ◽  
Etlingera Elatior

Background: Etlingera elatior (Ee) contains phytochemical compounds that are rich in antioxidants, which may reduce several biochemical markers of metabolic syndrome (MetS). Objective: We aimed to study the effect of fresh Etlingera elatior (FEe) and steamed Etlingera elatior (SEe) as a part of rat diet on the body weight, serum lipid, and malondialdehyde (MDA) level in Wistar rats with MetS induced by a highfat, high-fructose diet. Method: Our research was a true experimental randomized control group design with pre- and post-test. A total of 24 male Wistar rats were divided randomly into the following four groups: 1) Control, fed standard rat diet during the whole duration of the study, 2) HFFr-Sd, fed high-fat high-fructose (HFFr) diet for 29 days, followed by 29 days of the standard diet, 3) HFFr-FEe, fed HFFr diet for 29 days, followed by 29 days of a standard diet containing 33.3% FEe, and 4) HFFrSEe, fed HFFr diet for 29 days, followed by 29 days of a standard diet containing 33.3% SEe. The HFFr diet was given at 15 g/day along with fructose drink (20% pure fructose) at 100 ml/day. The diets in each group after the MetS induction period is referred to as intervention diets. Data at the end of HFFr (pre) and intervention diets (post) were analyzed by paired t-test. The data among groups were analyzed by one-way analysis of variance followed by post hoc test. Results: HFFr diet for 29 days induced MetS in Wistar rats fulfilling the criteria of obesity (Lee Index), hypertriglyceridemia, and decreased high-density lipoprotein cholesterol (HDL-C). Also, there was a significant increase in serum total cholesterol, low-density lipoprotein cholesterol (LDL-C), and MDA level (p < 0.05). Feeding a diet contaning FEe or SEe can significantly reduce body weight, serum triglyceride, total cholesterol, LDL-C, and MDA, and increase HDL-C levels (p < 0.05). The effect of FEe was more pronounced in ameliorating body weight and lipid profile than SEe. Conclusion: Fresh Ee and Steamed Ee can ameliorate obesity, dyslipidemia, and oxidative stress in MetS Wistar rats induced by a high-fat high-fructose diet. It suggests that dietary Ee accounting for one-third of daily standard diet can assist in normalizing some MetS markers in rats.

scholarly journals Potential Role of Novel Myokine in Rats-Induced Metabolic Syndrome

2021 ◽  
Vol 12 (3) ◽  
pp. 3305-3315
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Potential Role ◽  
Serum Levels ◽  
Treated Group ◽  
Control Group ◽  
Standard Diet ◽  
The Metabolic Syndrome ◽  
Obesity And Diabetes ◽  
Increased Risk

One of the main health problems is metabolic syndrome (MetS). Its incidence elevates with age leading to a higher risk of evolving chronic diseases and cancer. Obesity and insulin resistance was considered the most vital components in its pathogenesis for a long time. This study aims to evaluate serum novel adipokine and myokine to establish the irrelation of insulin resistance and their impact on metabolic syndrome. Four groups of rats were included; the control group (C) fed with a standard diet, the second group (CI) fed on a standard diet and injected daily with irisin (100ng/ ml) till the end of the experiment. The third group (MetS group) fed on the HCHF diet for 20 weeks and served as a control group. Rats in the fourth group (MetS+I group) were fed on the HCHF diet until they become obese and diabetic, then injected daily with irisin (100ng/ ml) till the end of the experiment and served as a treated group. Serum levels of obesity and diabetes indices were significantly increased while HDL was significantly decreased in the metabolic syndrome group, but after treatment with irisin, their levels were improved. Both adropin and irisin were significantly decreased, while IL-6 was significantly increased in the same group that was enhanced after irisin treatment. In conclusion, this study demonstrated that lower irisin correlates with the increased risk of increased risk of insulin resistance and MetS. In addition, our results suggested that irisin could have a potential role in glucose metabolism. The relations among increased levels of circulating irisin, insulin resistance, and MetS prevalence may be elucidated with a physiological compensatory contrivance.

scholarly journals AB0871 OSTEOARTHRITIS IN OBESE PATIENTS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1741.1-1742
Author(s):  
S. Lapshina ◽  
L. Feiskhanova ◽  
A. Nurmieva ◽  
K. Sadriev
Keyword(s):  
Metabolic Syndrome ◽  
Body Weight ◽  
Normal Weight ◽  
Knee Joints ◽  
Excess Body Weight ◽  
Obese Patients ◽  
Obese People ◽  
X Ray ◽  
The Metabolic Syndrome ◽  
Increased Risk

Background:Obesity is a recognized risk factor for osteoarthritis (OA) of the knee joints, which is associated with increased biomechanical stress. However, the association of OA with metabolic syndrome is more multifaceted, since overweight and obese people have a similar increased risk of OA of the hand joints that do not carry weight, due to systemic factors.Objectives:To identify the features of the course of OA in overweight patients.Methods:52 patients with an established diagnosis of osteoarthritis were examined: women - 84.6%, men - 15.4%, average age - 60.9 ± 8.9 years (32 to 78 years). Clinical examination, calculation of body mass index (BMI), determination of the X-ray stage of OA according to the Kellgren and Lawrence system; ultrasound examination of the knee joints; assessment of the severity of pain according to visual analog scale (VAS); the index WOMAC was used to evaluate pain, stiffness and physical function. We evaluated the quality of life by EQ-5D.Results:The duration of OA was 8.75 [2.58; 26] years. The distribution of patients according to the X-ray stage of OA: I - 9.6%, II - 57.6%, III - 26.9%, IV - 5.9% of patients. The BMI range was from 21 to 43 kg/. A BMI up to 30 kg/ was found in 22 patients: 17.3% - normal weight, 25% - excess body weight. Thirty patients has BMI more than 30 kg/: I degree - 38.4%, II degree - 15.3%, III degree - 4%. Obese patients rated pain according to the VAS scale of 1.3 the score is more intensively than patients with a BMI <30 kg/m2(p <0.001). A detailed examination of each subsequent degree of obesity revealed a tendency to reduce the pain syndrome from 7.52 points at 1 degree of obesity to 5 points at 3 degrees of obesity (p <0.001). With increasing body weight, there was an increase in difficulties in daily activities according to the WOMAC (p <0.05). Reactive knee synovitis was detected in 25 (48%) patients. The incidence of synovitis in patients with a BMI <30 kg / m2is 27%, with a BMI> 30 kg / m2is 68%. Patients with obesity of 1stdegree had synovitis in 65%, 2nddegree - 75%, 3rddegree - 84% of cases (p <0.05). A high correlation between the x-ray stage of OA and BMI (r = 0.74; p <0.001) was revealed. According to the EQ-5D questionnaire, patients with the 1stdegree of obesity (2.31 ± 1.3) were very anxious, but the level of anxiety decreases in patients with 3rddegree of obesity (1.44 ± 0.9) and it’s equal to that in individuals with normal body weight (1.33 ± 0.8).Conclusion:The existence of obesity in patients with OA is associated with an increase in pain, a significant decrease in functional ability, a presence of reactive synovitis of the knee joints, aggravation of the X-ray stage of OA, and the appearance of anxiety and depression. However, with the further progression of obesity, the levels of anxiety for one’s condition decrease.References:[1]Felson DT, Zhang Y, Hannan MT et al. Risk factors for incident radiographic knee osteoarthritis in the elderly: the Framingham study. Arthritis Rheum. 1997; 40: 728–733.[2]Huffman KM. Osteoarthritis and the metabolic syndrome: more evidence that the etiology of OA is different in men and women. 2012; 20 (7): 603–604.Disclosure of Interests:None declared

Prevalence of metabolic syndrome in never treated mood disordered patientss

2007 ◽  
Vol 30 (4) ◽  
pp. 95
Author(s):  
Valerie Taylor ◽  
Glenda M. MacQueen
Keyword(s):  
Metabolic Syndrome ◽  
Mood Disorders ◽  
Population Attributable Risk ◽  
Disease Process ◽  
Visceral Obesity ◽  
Premature Mortality ◽  
Overweight And Obesity ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Bipolar Patients

Bipolar disorder and major depression are life-shortening illnesses. Unnatural causes such as suicide and accidents account for only a portion of this premature mortality1 Research is beginning to identify that mood disordered patients have a higher incidence of metabolic syndrome, an illness characterized by dyslipidemia, impaired glucose tolerance, hypertension and obesity.2 Metabolic syndrome is associated with an increased risk for a variety of physical illnesses. Hypothesis: Never treated patients with mood disorders have preexisting elevations in the prevalence of the component variables of metabolic syndrome. Central obesity will be especially elevated, predicting increased premature mortality. Methods: We assessed never treated patients with mood disorders for metabolic syndrome and its component variables. Patients were assessed at baseline and followed up at 6-month intervals. All psychiatric pharmacotherapy was documented. Body mass index (BMI) was also obtained and the percentage of deaths attributable to overweight and obesity was calculated using the population attributable risk (PAR). [PAR= ∑[P (RR-1)/RR] Results: Prior to the initiation of treatment, patients did not differ from population norms with respect to metabolic syndrome or BMI. At 2-year follow-up, BMI had increased for unipolar patients 2.02 points and 1.92 points for bipolar patients. (p < .001) This increase in BMI predicted an increase in mortality of 19.4%. Conclusion: An increase in visceral obesity is often the first component of metabolic syndrome to appear and may indicate the initiation of this disease process prematurely in this group. The increase in BMI places patients with mood disorders at risk for premature mortality and indicates a need for early intervention. References 1.Osby U, Brandt L, Correia N, Ekbom A & Sparen P. Excess mortability in bipolar and Unipolar disorder rin Sweden. Archives of General Psychiatry, 2001;58: 844-850 2.Toalson P, Saeeduddin A, Hardy T & Kabinoff G. The metabolic syndrome in patients with severe mental illness. Journal of Clinical Psychiatry, 2004; 6(4): 152-158

Metabolic Syndrome During Menopause

2019 ◽  
Vol 17 (6) ◽  
pp. 595-603 ◽  
Author(s):  
Sezcan Mumusoglu ◽  
Bulent Okan Yildiz
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Central Obesity ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Natural Menopause ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Aging Women

The metabolic syndrome (MetS) comprises individual components including central obesity, insulin resistance, dyslipidaemia and hypertension and it is associated with an increased risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). The menopause per se increases the incidence of MetS in aging women. The effect(s) of menopause on individual components of MetS include: i) increasing central obesity with changes in the fat tissue distribution, ii) potential increase in insulin resistance, iii) changes in serum lipid concentrations, which seem to be associated with increasing weight rather than menopause itself, and, iv) an association between menopause and hypertension, although available data are inconclusive. With regard to the consequences of MetS during menopause, there is no consistent data supporting a causal relationship between menopause and CVD. However, concomitant MetS during menopause appears to increase the risk of CVD. Furthermore, despite the data supporting the association between early menopause and increased risk of T2DM, the association between natural menopause itself and risk of T2DM is not evident. However, the presence and the severity of MetS appears to be associated with an increased risk of T2DM. Although the mechanism is not clear, surgical menopause is strongly linked with a higher incidence of MetS. Interestingly, women with polycystic ovary syndrome (PCOS) have an increased risk of MetS during their reproductive years; however, with menopausal transition, the risk of MetS becomes similar to that of non-PCOS women.

scholarly journals Is depression a cause of metabolic abnormality? A European Small State experience

2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
S Cuschieri
Keyword(s):  
Metabolic Syndrome ◽  
Cholesterol Level ◽  
Fasting Blood Glucose ◽  
Depression Symptoms ◽  
Health Examination ◽  
High Cholesterol ◽  
Small State ◽  
The Metabolic Syndrome ◽  
High Cholesterol Level ◽  
Increased Risk

Abstract Background A relationship between depression and metabolic syndrome has been reported. Considering the diabesity rates effecting the small state of Malta it was considered appropriate to explore for links between these diseases, their metabolic determinants with depression. Methods A national health examination survey was conducted. A validated questionnaire note down (1) self-reported depression (2) anti-depressive medication (3) PHQ-9 depression symptoms score (&gt;5 positive for depression). Participants with the presence of one or more of these variables were labelled as having depression. Body mass index (BMI), waist circumference (WC) and blood pressure (BP) were measured. Blood testing for fasting blood glucose (FBG) and lipid profile were performed. The biochemical (FBG, Lipid profiles) and anthropometric profiles (BMI, WC, BP) of the depression population were compared to those without this disease. Univariant and multivariant binary logistic regression models were performed. Results The depression population (17.2% of the total population) had significantly higher median LDL, triglyceride (TG) and total cholesterol (TC) levels when compared to those without the disease (p = &lt;0.01). On univariant modelling each variable (LDL OR:1.15 p = 0.01; TG OR:1.16 p = 0.01; TC OR:1.64 p = &lt;0.01) showed a positive association with having depression even after adjusting for confounding factors (sex, age, education, smoking, alcohol habits). On multivariant modelling only an increase in TC was associated with increased risk of having depression (OR: 1.36 CI95%: 1.05-1.76 p = 0.02) after adjusting for confounders. Conclusions The various components of the metabolic syndrome appeared not to be associated with a diagnosis of depression. Only high cholesterol level exhibited a metabolic link with depression. Although further research is merited, it is suggested that physicians incorporate a depression screening tool as part of their consultation when examining high-risk patients. Key messages A metabolic syndrome profile is not linked with depression. A high cholesterol level is linked with depression, making these individuals susceptible to potential cardiovascular disease.

Sign in / Sign up

Export Citation Format

Share Document